Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice

Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial

(2016) Ligia A. Pinto et al.   JOURNAL OF INFECTIOUS DISEASES

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody

(2015) Daning Wang et al.   PLoS One

Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions

(2014) Joshua W. Wang et al.   PLoS One

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica

(2013) Rolando Herrero et al.   PLoS One

Reducing HPV-Associated Cancer Globally

(2012) D. R. Lowy et al.   Cancer Prevention Research

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

(2011) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

A Murine Genital-Challenge Model Is a Sensitive Measure of Protective Antibodies against Human Papillomavirus Infection

(2011) S. Longet et al.   JOURNAL OF VIROLOGY

Antibody Responses in Oral Fluid after Administration of Prophylactic Human Papillomavirus Vaccines

(2009) Ali Rowhani‐Rahbar et al.   JOURNAL OF INFECTIOUS DISEASES

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

(2009)   LANCET

Distinct Risk Factor Profiles for Human Papillomavirus Type 16–Positive and Human Papillomavirus Type 16–Negative Head and Neck Cancers

(2008) Maura L. Gillison et al.   JNCI-Journal of the National Cancer Institute